Shanghai Pharmaceuticals Holding (02607) announced its interim results, with a net profit attributable to shareholders of approximately 3.504 billion yuan, a year-on-year decrease of 21.4%.

Shanghai Pharmaceuticals Holding (02607) announced its mid-year performance for 2026, with operating revenue of approximately 147.47 billion yuan, a year-on-year increase of 4.15%; net profit attributable to shareholders of the listed company was about 3.504 billion yuan, a year-on-year decrease of 21.4%; basic earnings per share were 0.95 yuan. The announcement stated that the decrease in profit was mainly due to fluctuations in one-time special gains and losses. After excluding these one-time special gains and losses, the net profit attributable to shareholders was 2.828 billion yuan, a year-on-year increase of 1.65%. Of this, the industrial segment contributed a profit of 1.343 billion yuan, a year-on-year increase of 1.51%; the commercial segment contributed a profit of 1.794 billion yuan, unchanged compared to the previous year; major equity investees contributed a profit of 0.078 billion yuan; the net profit attributable to shareholders after deducting non-recurring gains and losses was 2.477 billion yuan, a year-on-year increase of 17.98%.